Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shionogi & Co ( (JP:4507) ).
Shionogi and its subsidiary Torii Pharmaceutical have applied in Japan for manufacturing and marketing approval of a new 0.5% lotion formulation of CORECTIM, a non-steroidal topical JAK inhibitor used to treat atopic dermatitis. The existing ointment form is already approved for adults, children, and infants, and the lotion aims to offer easier application, particularly on the scalp and other hairy areas where ointments are less practical.
The approval bid is supported by positive Phase 1 skin safety data and a Phase 3 bioequivalence study showing comparable safety and bioequivalence to the current 0.5% ointment. If approved, the lotion is expected to improve treatment adherence and quality of life for patients with this chronic inflammatory skin disease, reinforcing Shionogi and Torii’s positioning in the atopic dermatitis market while complementing global commercialization of delgocitinib through LEO Pharma under the Anzupgo brand.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen4247.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company focused on prescription drugs, including treatments for infectious, metabolic, and immunological diseases. Through its wholly owned subsidiary Torii Pharmaceutical, Shionogi also develops and co-promotes dermatology products, targeting chronic inflammatory skin conditions such as atopic dermatitis in the domestic market.
Torii Pharmaceutical specializes in dermatological therapies and serves as a key commercialization partner for Shionogi in Japan. Together, the group leverages Shionogi’s R&D capabilities and Torii’s dermatology franchise to expand topical treatment options, while international rights for some assets, such as delgocitinib, are licensed to global players like LEO Pharma.
Average Trading Volume: 2,916,328
Technical Sentiment Signal: Buy
Current Market Cap: Yen3192.7B
For a thorough assessment of 4507 stock, go to TipRanks’ Stock Analysis page.